Details for New Drug Application (NDA): 021817
✉ Email this page to a colleague
The generic ingredient in RECLAST is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.
Summary for 021817
Tradename: | RECLAST |
Applicant: | Sandoz |
Ingredient: | zoledronic acid |
Patents: | 1 |
Suppliers and Packaging for NDA: 021817
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RECLAST | zoledronic acid | INJECTABLE;INTRAVENOUS | 021817 | NDA | Novartis Pharmaceuticals Corporation | 0078-0435 | 0078-0435-61 | 100 mL in 1 BOTTLE (0078-0435-61) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | EQ 5MG BASE/100ML | ||||
Approval Date: | Apr 16, 2007 | TE: | AP | RLD: | Yes | ||||
Patent: | 7,932,241*PED | Patent Expiration: | Aug 5, 2028 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 021817
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sandoz | RECLAST | zoledronic acid | INJECTABLE;INTRAVENOUS | 021817-001 | Apr 16, 2007 | 4,939,130*PED | ⤷ Subscribe |
Sandoz | RECLAST | zoledronic acid | INJECTABLE;INTRAVENOUS | 021817-001 | Apr 16, 2007 | 8,052,987 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription